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Abstract
Bacterial vaginosis is a genital tract infection, thought to be caused by transformation of a lactobacillus-rich lora to a dys-
biotic microbiota enriched in mixed anaerobes. The most prominent of these is Gardnerella vaginalis (GV), an anaerobic 
pathogen that produces sialidase enzyme to cleave terminal sialic acid residues from human glycans. Notably, high sialidase 
activity is associated with preterm birth and low birthweight. We explored the potential of the sialidase inhibitor Zanamavir 
against GV whole cell sialidase activity using methyl–umbelliferyl neuraminic acid (MU-NANA) cleavage assays, with 
Zanamavir causing a 30% reduction in whole cell GV sialidase activity (p < 0.05). Furthermore, cellular invasion assays using 
HeLa cervical epithelial cells, infected with GV, demonstrated that Zanamivir elicited a 50% reduction in cell association 
and invasion (p < 0.05). Our data thus highlight that pharmacological sialidase inhibitors are able to modify BV-associated 
sialidase activity and inluence host–pathogen interactions and may represent novel therapeutic adjuncts.
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Introduction
Bacterial vaginosis (BV) is a prevalent condition character-
ised by vaginal irritation and malodour. It is hypothesised 
in BV that the vaginal microbiome alters from a rich lacto-
bacilli flora; to a dysbiotic population rich in mixed anaer-
obes with Gardnerella vaginalis (GV) prominent (Ling et al. 
2010; Brocklehurst et al. 2013). Often asymptomatic, BV 
is a risk factor for Pelvic Inlammatory disease, sexually 
transmitted infections and post-operative infections (Cauci 
et al. 2005; Allsworth and Peipert 2007; Lewis et al. 2013; 
Schwebke et al. 2014). BV increases risk of preterm birth 
(PTB), with reduction in lactobacilli and increased mixed 
anaerobes strongly correlating with increased PTB risk 
(Cauci et al. 2005; Nelson et al. 2009; Marrs et al. 2012; 
Marconi et al. 2013; Bretelle et al. 2015). Furthermore, 
blanket antibiotic treatment does not reduce the incidence 
of PTB and so a more targeted approach may be required 
(McDonald et al. 2007; Marrs et al. 2012; Romero et al. 
2014).
One prominent trait of the dysbiotic microbiota in BV is 
production of high levels of sialidase enzymes produced by 
bacteria that act to release sialic acid, the terminal glycan on 
many glycoproteins in secretions and on mucosal cell sur-
faces- including vaginal mucous (Severi et al. 2007; Staford 
et al. 2011; Lewis et al. 2012; Hardy et al. 2017). This sialic 
acid is used by pathogens as a mechanism of adherence to 
cellular and inert surfaces, as a source of nutrition and also 
modiies the normal mucus barrier and immune response 
(Amith et al. 2009, 2010; Staford et al. 2011; Lewis et al. 
2012, 2013; Vick et al. 2014). Evidence suggests BV in con-
junction with high sialidase activity is predictive of PTB and 
low birthweight, while BV alone is not (Cauci et al. 2005).
The most prominent and well-studied bacterium in BV 
is G. vaginalis; a Gram Variable anaerobic coccobacillus 
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with a thin Gram-positive type cell wall (Cauci et al. 2005; 
Marrs et al. 2012; Lewis et al. 2013; Castro et al. 2015). 
Many strains of G. vaginalis are sialidase positive, with 
activity likely related to pathogenesis and virulence and 
potentially for survival in this environment (Cauci et al. 
2005; Lopes Dos Santos Santiago et al. 2011; Gilbert et al. 
2013; Lewis et al. 2013; Hardy et al. 2017). In addition, 
genome sequencing of G. vaginalis strains has revealed three 
main clade ecotypes, with all except clade 3B containing 
putative sialidase genes (Cornejo et al. 2018). Given the 
prominence and likely importance of sialidase activity in 
BV infections, we set out in this pilot study to test whether 
the sialidase inhibitor Zanamivir  (Relenza®), might inhibit 
GV sialidase activity, and determine how this might afect 
its reported interaction with human cervical epithelial cells 
in vitro (Hardy et al. 2017).
Methods
Bacterial strains and growth media
Gardnerella vaginalis, strains JCP8017A and JCP8066 
[clades 2A and 2B, respectively (Cornejo et al. 2018)], 
obtained through BEI Resources, NIAID, NIH as part of 
the Human Microbiome Project, and checked on arrival 
microscopically and by 16s rRNA sequencing. These were 
cultured on Casman  Agar® (BD, UK) with 10% oxalated 
horse blood (Oxoid, Fisher Scientiic, UK) in a Don Whitley 
MiniMacs anaerobic cabinet (10%  CO2, 10%  H2, and 80% 
 N2) at 37 °C for 72 h.
Whole cell sialidase assays
3-day-old bacterial colonies were transferred into 1 ml of 
sterile phosphate-bufered saline (PBS, pH 7.4) and centri-
fuged at 10,000×g for 1 min and washed three times before 
dilution to an A600 of 1.0 with 10 µl added to each reac-
tion mix containing 0.2 mM MUNANAC (Carbosynth), 
in 20 mM Tris–HCl (pH 7.4) or 100 mM sodium acetate 
(pH 5.5): total volume 100 µl, for 1 h. Reactions were incu-
bated at 37 °C in an anaerobic cabinet in the presence or the 
absence of Zanamivir  (Relenza®) 10 mM (a concentration 
previously established to inhibit oral anaerobe sialidases, 
Staford, unpublished). Readings of luorescence (excita-
tion 370 nm emission 420 nm) were measured as indicated 
(REF).
Host–pathogen invasion assay
HeLa cells were cultured in a sterile cabinet using Dulbec-
co’s Modiied Eagle’s Media (DMEM) (Sigma, Poole) with 
10% fetal calf serum (Sigma, Poole), 1% 2 mM glycerine 
(Bio Whitlaker DE14-870FH), and 1% Pen/strep (10,000 
units Penicillin, 10 mg Streptomycin per ml) (Sigma, Poole). 
Cells were grown to 70–80% conluence and split every 3–4 
days using trypsin EDTA (Sigma, Poole).
Invasion assays were performed as previously described 
(Naylor et al. 2017). In brief, 2.0 × 105 HeLa cells were 
seeded in 24-well tissue-culture plates overnight in media 
without pen/strep, before washing with PBS and incubated 
for 1 h at 37 °C, 5%  CO2 in DMEM with 2% bovine serum 
albumin (BSA) (Sigma, Poole). Following incubation, BSA 
solution was removed and cells washed in PBS, before GV 
JCP8066 was added at a multiplicity of infection (MOI) 
of 1:100 with or without Zanamivir (10 mM) for 90 min 
at 37 °C 5%  CO2. Cells were then washed with PBS to 
remove unattached bacteria. For total bacterial counts, cells 
were lysed before being plated on Casman agar using the 
Miles–Misra method (Miles et al. 1938). To determine bac-
terial invasion counts, wells were treated with metronidazole 
200 µg/ml to kill extracellular bacteria and incubated for 1 h 
at 37 °C, and 5%  CO2 conditions we have tested and shown 
to reduce viable counts of GCV8066 by 3-logs (not shown). 
Following incubation, cells were lysed and colonies counted, 
before invasion etc. calculated as a percentage of the viable 
count of the initial innoculum.
All experiments were repeated in technical triplicate 
with three biological repeats. Statistical diference between 
groups was established using Students t test. Cytotox 96 
 assays® (Promega, UK) were performed to conirm non-
toxicity of the drugs (data not shown).
Results
Inhibition of whole G. vaginalis cell sialidase activity 
by Zanamivir
Sialidase assays examined if bacterial sialidase activity 
could be directly inhibited by the sialidase inhibitor Zan-
amivir, marketed as  Relenza®. This was chosen, because we 
aimed to study a drug used clinically with a well-established 
safety proile. First, Zanamavir is approved for clinical use 
by the FDA for inluenza treatment. Second, unlike oseltami-
vir phosphate (active agent in  TamiFlu®), application as a 
topical agent may be feasible as  TamiFlu® requires liver 
metabolism into an active form, while Zanamivir is efec-
tive when used in a topical form and supplied as an aerolised 
powder for inhalation into the lungs of inluenza suferer. 
Moreover, it is safe in pregnancy and has been used topically 
safely in man (Hayden et al. 1997; Xie et al. 2013; Jeferson 
et al. 2014).
We tested inhibition of two sialidase positive strains of 
G. vaginalis, namely, GV JCP8066 and GV 8017A, which 
are members of GV clade 2A and 2B (Lewis et al. 2013; 
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Cornejo et  al. 2018) in whole cell bacterial sialidase 
assays (where both cell associated and enzyme released 
by cells during the assay time course would be present) 
using 10 mM Zanamivir at both neutral and acidic pH—
pH 5.5 was chosen as it had previously been shown to be 
the optimum pH for this enzyme (von Nicolai et al. 1984); 
notable vaginal pH is normally around 4.5 and is raised 
in BV (Cauci et al. 2005; Gilbert et al. 2013). In both G. 
vaginalis strains, and at both pH values tested, Zanami-
vir significantly (p < 0.05), reduced sialidase activity of 
whole bacterial G. vaginalis cells up to 30% at 10 mM 
(N.B. this was the highest concentration achievable in 
solution in these assay conditions, and a dose achievable 
potentially clinically, where a 10 mg dose is given 4× per 
day) (Fig. 1).
Efect of Zanamivir on bacterial invasion of human 
cervical cells
We then utilised strain GV JCP8066 in antibiotic protection 
assays chosen, since in preliminary studies, it displayed the 
most stable growth and aerotolerance in preliminary stud-
ies (data not shown). We performed invasion assays at an 
MOI of 1:100, and observed association and invasion rates 
of approximately 1%; typical of invasion rates our labora-
tory commonly observes for oral anaerobes such as Porphy-
romonas gingivalis, Tannerella forsythia, and Fusobacte-
rium spp. (Naylor et al. 2017). In contrast, assays performed 
in the presence of Zanamivir, displayed a dramatic, and 
statistically signiicant reduction in levels of total associa-
tion (2.2-fold, p = 0.03), adhesion (1.95-fold, p = 0.04), and 
invasion (2.4-fold, p = 0.03) (Fig. 2). Indicating Zanamivir 
can reduce cellular internalisation of G. vaginalis by approx-
imately twofold under the conditions tested (Fig. 2).
Fig. 1  Inhibition of whole cell G. vaginalis sialidase by Zanamivir 
(10 mM). Whole bacteria (strains as indicated) were incubated with 
Zanamivir in the presence of MU-NANA (0.2 mM) as described for 
1  h. Sialidase activity was measured using readings of luorescence 
(excitation 370  nm emission 420  nm). Activity was calculated as a 
percentage of sialidase activity seen with no inhibitor (Con). Assays 
were conducted at a pH 7.4 and pH 5.5 as indicated. Students’ t test 
was used to calculate signiicant diferences between con and drug, 
and noted in A (n = 3). Error bars are ± standard error of the mean 
(SEM). Fig produced using GraphPad Prism
Fig. 2  Inluence of Zanamavir on host–pathogen interaction of G. 
vaginalis with cervical cells. HeLa cell monolayers were infected 
with G. vaginalis strain JCP8066. Total association, cell membrane 
adhered (attached), and invaded cells were calculated as described in 
methods. Bacteria were counted as colony forming units (CFU) and 
calculated as a percentage of viability from the bacterial inoculum 
CFUs (n = 3). Students’ t test used to calculate signiicance and noted 
as **p < 0.05. Error bars are ± SEM. Fig produced using GraphPad 
Prism
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Discussion
In this study, we established that Zanamivir reduces two 
facets of the virulence of the BV-associated pathogen 
G. vaginalis, namely, its sialidase activity and ability to 
invade Human cells. However, we also acknowledge here 
that our sialidase activity assays only focussed on an arti-
icial substrate, albeit a widely used compound to assess 
sialidase activity, and that in vivo sialidase act upon a wide 
range of more complex glycans with varying levels of pref-
erence and activity. In addition, it may be that the inhibitor 
used here also had varied inhibitory activity on these vary-
ing substrate–enzyme interactions, a picture that would 
be improved by performing further assays with complex 
glycans and a range of strains.
This observation is similar to other sialidase positive 
pathogens, where sialidase activity is linked to the ability 
to adhere to glycoproteins and invade (and thus potentially 
damage) epithelial cells (Honma et al. 2011; Roy et al. 
2011). Indeed, G. vaginalis and an increased sialidase 
activity from vaginal samples are associated with disease 
and increased risk of PTB (Simhan et al. 2003; Cauci et al. 
2005; Bretelle et al. 2015). In addition, symptomatic BV 
cases tend to be associated sialidase positive readings of 
swabs (Lopes Dos Santos Santiago et al. 2011). Evidence 
thus suggests that sialidase activity of these strains has 
evolved as an adaptation to life in a glycan rich niche and 
may aid pathogenesis. Thus directly targeting pathogens 
that possess sialidase activity might be an alternative 
approach to antibiotic treatment for BV during pregnancy, 
since antibiotics have been shown to have no efect on the 
incidence of PTB (McDonald et al. 2007).
Our data indicate that Zanamavir reduces sialidase 
activity, but also impairs the ability of G. vaginalis to 
invade human cells. This may have import in BV, since 
the ability to enter epithelial cells is considered both a 
strategy to evade the immune system, but may also lead 
to formation of transient intracellular reservoirs of bacte-
ria that can recolonize the mucosa and microbiota (Marrs 
et al. 2012). Of note is also that any intracellular bacteria 
are also able to evade antibiotic treatment requiring new 
approaches to treat them or preventing their invasion (Ran-
jan et al. 2012).
Another potential beneicial factor to sialidase inhibi-
tion is that it is now clear that sialidases can inluence 
innate immune responses to bacteria by modulating the 
levels of sialic acid on key innate immune receptors such 
as Toll-like receptors 2 and 4 (Amith et al. 2010). This is 
the case for both bacterial (Amith et al. 2009) and human 
sialidases (NEU1 and NEU3), both of which are inhibited 
by Zanamavir, but which also contain more complex gly-
cans (Hata et al. 2008). Thus, by inhibiting either bacterial 
or human sialidases pharmacologically, there is the poten-
tial to reduce inlammation. In addition, sialidase targets 
IgA-key to inhibiting adhesion of bacteria at mucosal sur-
faces, meaning that inhibition of sialidase in vivo may also 
decrease bacterial adhesion by maintaining functional IgA 
(Lewis et al. 2012).
The inal efect of reducing sialidase levels would be to 
reduce the amount of free sialic acid for bacterial growth, 
and hence starving certain bacteria of a key nutrient. This 
potential to decrease free sialic acid may have other knock-
on efects with evidence from mouse models that sialidases 
may have a role in promoting growth of group B streptococci 
by releasing free sialic acid, and potentially the propagation 
of ascending genital tract infection (Pezzicoli et al. 2012; 
Gilbert et al. 2013). Given the poly-microbial nature of BV, 
it seems plausible that targeting this metabolic activity has 
the potential to manipulate the microbiota to suppress siali-
dase positive BV pathogens and potentially promote rebio-
sis to a lactobacillus dominate community, although further 
experiments in a poly-microbial model of the vaginal micro-
biota are necessary.
However, we are aware that our study is limited, with a 
need for expansion of the repertoire of species used, range 
of drugs tested and potentially using primary vaginal cells. 
In addition, as mentioned above, sialidase activity can inlu-
ence innate immune responses and it would be of interest 
to establish whether inhibitors reduce pro-inlammatory 
cytokine production, as is the case for S. pneumoniae (Paul-
son and Kawasaki 2011).
In conclusion, we have established the anti-inluenza 
drug Zanamivir can inhibit GV sialidase and influence 
host–pathogen interactions in vitro, suggesting future direc-
tions for investigation and potential of these drugs as topi-
cally applied adjuncts for BV treatment and reduction of 
associated morbidities.
Acknowledgements GV was supported by Jessop Wing Small Grant 
Scheme and the National Institute of Health Research, while KN and 
AF were supported by a Sheield University PhD studentship and the 
BBSRC (BB/K501098/1). JLP was funded by an MRC DPFS Grant to 
DA (MR/J014788/1).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
Archives of Microbiology 
1 3
References
Allsworth JE, Peipert JF (2007) Prevalence of bacterial vaginosis: 
2001–2004 National Health and Nutrition Examination Survey 
data. Obstet Gynecol 109:114–120
Amith SR, Jayanth P, Franchuk S et al (2009) Dependence of pathogen 
molecule-induced toll-like receptor activation and cell function on 
Neu1 sialidase. Glycoconj J 26:1197–1212
Amith SR, Jayanth P, Franchuk S et al (2010) Neu1 desialylation of 
sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like 
receptor 4 is essential for receptor activation and cellular signal-
ing. Cell Signal 22:314–324
Bretelle F, Rozenberg P, Pascal A et al (2015) High Atopobium vagi-
nae and Gardnerella vaginalis vaginal loads are associated with 
preterm birth. Clin Infect Dis 60:860–867
Brocklehurst P, Gordon A, Heatley E, Milan SJ (2013) Antibiotics for 
treating bacterial vaginosis in pregnancy. Cochrane Database Syst 
Rev. https ://doi.org/10.1002/14651 858.CD000 262.pub4
Castro J, Alves P, Sousa C et al (2015) Using an in-vitro bioilm model 
to assess the virulence potential of bacterial vaginosis or non-bac-
terial vaginosis Gardnerella vaginalis isolates. Sci Rep 5:11640
Cauci S, McGregor J, Thorsen P et al (2005) Combination of vagi-
nal pH with vaginal sialidase and prolidase activities for predic-
tion of low birth weight and preterm birth. Am J Obstet Gynecol 
192:489–496
Cornejo OE, Hickey RJ, Suzuki H, Forney LJ (2018) Focusing the 
diversity of Gardnerella vaginalis through the lens of ecotypes. 
Evol Appl 11:312–324
Gilbert NM, Lewis WG, Lewis AL (2013) Clinical features of bacterial 
vaginosis in a murine model of vaginal infection with Gardnerella 
vaginalis. PLoS One 8:e59539
Hardy L, Jespers V, Van den Bulck M et al (2017) The presence of 
the putative Gardnerella vaginalis sialidase A gene in vaginal 
specimens is associated with bacterial vaginosis bioilm. PLoS 
One 12:e0172522
Hata K, Koseki K, Yamaguchi K et al (2008) Limited inhibitory efects 
of oseltamivir and zanamivir on human sialidases. Antimicrob 
Agents Chemother 52:3484–3491
Hayden FG, Osterhaus AD, Treanor JJ et al (1997) Eicacy and safety 
of the neuraminidase inhibitor zanamivir in the treatment of inlu-
enzavirus infections. N Engl J Med 337:874–880
Honma K, Mishima E, Sharma A (2011) Role of Tannerella for-
sythia NanH sialidase in epithelial cell attachment. Infect Immun 
79:393–401
Jeferson T, Jones MA, Doshi P et al (2014) Neuraminidase inhibitors 
for preventing and treating inluenza in healthy adults and chil-
dren. Cochrane Database Syst Rev 4:CD008965
Lewis WG, Robinson LS, Perry J et  al (2012) Hydrolysis of 
secreted sialoglycoprotein immunoglobulin A (IgA) in ex vivo 
and biochemical models of bacterial vaginosis. J Biol Chem 
287:2079–2089
Lewis WG, Robinson LS, Gilbert NM et  al (2013) Degradation, 
foraging, and depletion of mucus sialoglycans by the vagina-
adapted Actinobacterium Gardnerella vaginalis. J Biol Chem 
288:12067–12079
Ling Z, Kong J, Liu F et al (2010) Molecular analysis of the diversity 
of vaginal microbiota associated with bacterial vaginosis. BMC 
Genom 11:488
Lopes Dos Santos Santiago G, Deschaght P, El Aila N et al (2011) 
Gardnerella vaginalis comprises three distinct genotypes of 
which only two produce sialidase. Am J Obstet Gynecol 204:450.
e1–450.e7
Marconi C, Donders GGG, Bellen G et al (2013) Sialidase activity in 
aerobic vaginitis is equal to levels during bacterial vaginosis. Eur 
J Obstet Gynecol Reprod Biol 167:205–209
Marrs CN, Knobel SM, Zhu WQ et al (2012) Evidence for Gardnerella 
vaginalis uptake and internalization by squamous vaginal epithe-
lial cells: implications for the pathogenesis of bacterial vaginosis. 
Microbes Infect 14:500–508
McDonald HM, Brocklehurst P, Gordon A (2007) Antibiotics for treat-
ing bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 
(1):CD000262
Miles AA, Misra SS, Irwin JO (1938) The estimation of the bacteri-
cidal power of the blood. J Hyg (Lond) 38:732–749
Naylor KL, Widziolek M, Hunt S et al (2017) Role of OmpA2 surface 
regions of Porphyromonas gingivalis in host-pathogen interac-
tions with oral epithelial cells. MicrobiologyOpen 6:1–11
Nelson DB, Hanlon A, Hassan S et al (2009) Preterm labor and bacte-
rial vaginosis-associated bacteria among urban women. J Perinat 
Med 37:130–134
Paulson JC, Kawasaki N (2011) Sialidase inhibitors DAMPen sepsis. 
Nat Biotechnol 29:406–407
Pezzicoli A, Ruggiero P, Amerighi F et al (2012) Exogenous sialic 
acid transport contributes to group B streptococcus infection of 
mucosal surfaces. J Infect Dis 206:924–931
Ranjan A, Pothayee N, Seleem MN et al (2012) Nanomedicine for 
intracellular therapy. FEMS Microbiol Lett 332:1–9
Romero R, Hassan SS, Gajer P et al (2014) The vaginal microbiota 
of pregnant women who subsequently have spontaneous preterm 
labor and delivery and those with a normal delivery at term. 
Microbiome 2:18
Roy S, Honma K, Douglas CWI et al (2011) Role of sialidase in 
glycoprotein utilization by Tannerella forsythia. Microbiology 
157:3195–3202
Schwebke JR, Muzny CA, Josey WE (2014) Role of Gardnerella 
vaginalis in the pathogenesis of bacterial vaginosis: a conceptual 
model. J Infect Dis 210:338–343
Severi E, Hood DW, Thomas GH (2007) Sialic acid utilization by bac-
terial pathogens. Microbiology 153:2817–2822
Simhan HN, Caritis SN, Krohn MA, Hillier SL (2003) Elevated vaginal 
pH and neutrophils are associated strongly with early spontaneous 
preterm birth. Am J Obstet Gynecol 189:1150–1154
Staford G, Roy S, Honma K, Sharma a (2011) Sialic acid, periodontal 
pathogens and Tannerella forsythia: stick around and enjoy the 
feast! Mol Oral Microbiol 26:11–22
Vick EJ, Park HS, Huf KA et al (2014) Gardnerella vaginalis triggers 
NLRP3 inlammasome recruitment in THP-1 monocytes. J Reprod 
Immunol 106:67–75
von Nicolai H, Hammann R, Salehnia S, Zilliken F (1984) A newly 
discovered sialidase from Gardnerella vaginalis. Zentralbl Bak-
teriol Mikrobiol Hyg A 258:20–26
Xie HY, Yasseen AS, Xie RH et al (2013) Infant outcomes among preg-
nant women who used oseltamivir for treatment of inluenza dur-
ing the H1N1 epidemic. Am J Obstet Gynecol 208:293.e1–293.e7
